Abstract

 CADTH recommends that Benlysta be reimbursed by public drug plans in addition to standard therapy for treatment of active lupus nephritis (LN) in adult patients.
 Benlysta should only be covered to treat adult patients with class III or IV, with or without class V, or pure class V active LN and who have started standard induction therapy within the previous 60 days. Benlysta should not be covered to treat patients who previously failed induction therapies or patients with an estimated glomerular filtration rate less than 30 mL/min/1.73 m2.
 Benlysta should only be reimbursed if prescribed by either a rheumatologist or nephrologist with experience managing LN and if the cost of Benlysta is reduced.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
